Keyphrases
Hyperoxia
99%
Hydrocortisone
77%
Pulmonary Hypertension
75%
Phosphodiesterase Type 5 Inhibitors
74%
Bronchopulmonary Dysplasia
73%
Pulmonary Artery Smooth muscle Cells (PASMCs)
56%
Oxidative Stress
51%
Persistent Pulmonary Hypertension of the Newborn
45%
Lamb
36%
Cyclic GMP
34%
Neonate
30%
Premature Infant
27%
Nitric Oxide Signaling
27%
Fetal Pulmonary Artery
27%
Pulmonary Vascular Development
27%
Hyperoxia-induced Lung Injury
25%
Murine Model
24%
Supplemental Oxygen
22%
Selective Intrauterine Growth Restriction (sIUGR)
21%
Delivery Room
21%
Oxygenation
21%
Pulmonary Vascular
21%
Extracellular Superoxide Dismutase (EC-SOD)
20%
Pulmonary Vascular Remodeling
19%
Room Air
19%
Lung Disease
18%
Perez
18%
Omics Studies
18%
Neonatal Lung
18%
Postnatal Growth Restriction
18%
Historical Perspective
18%
Oxygen Delivery
18%
Non-signaling
18%
Superoxide Dismutase 2 (SOD2)
18%
Oxygen Radical Diseases
18%
Low-dose Hydrocortisone
18%
Heart Failure
18%
Neonatal Rat Model
18%
Vascular Endothelial Growth Factor
18%
Total Superoxide Dismutase
18%
Neurodevelopmental Impairment
18%
Mitochondrial Oxidation
18%
Newborn Period
18%
Dose Effect
18%
Superoxide Dismutase 3 (SOD3)
18%
Severe Pulmonary Hypertension
18%
Superoxide Dismutase Activity
18%
Cyclic Guanosine Monophosphate Signaling
18%
Neurodevelopment
18%
Knock-in Mouse Model
18%
Medicine and Dentistry
Hyperoxia
100%
Neonatal Infant
80%
Pulmonary Hypertension
75%
Lung Dysplasia
70%
Phosphodiesterase V
63%
Pulmonary Artery Smooth Muscle Cell
56%
Hydrocortisone
54%
Oxidative Stress
53%
Cyclic GMP
31%
Prematurity
28%
Diseases
28%
Neonates
27%
Nitric Oxide
27%
Silo-Filler's Disease
26%
Persistent Fetal Circulation
25%
Newborn Period
21%
Intrauterine Growth Retardation
21%
Superoxide Dismutase
20%
Extracellular Superoxide Dismutase
20%
Signal Transduction
20%
Glucocorticoid
18%
Manganese Superoxide Dismutase
18%
Postnatal Growth
18%
Mitochondrial Respiration
18%
Low Drug Dose
18%
Oxygen Radical
18%
Nerve Cell Differentiation
18%
Resuscitation
18%
Tamsulosin
18%
Lung
18%
Pulmonary Artery
16%
Placebo
15%
Reactive Oxygen Species
15%
Alternative Complement Pathway C3 C5 Convertase
15%
Nuclear Factor
15%
Right Ventricular Hypertrophy
15%
Antioxidant
15%
Injury
14%
Vasculotropin
13%
Congestive Heart Failure
12%
Antioxidant Enzyme
11%
Vascular Remodeling
10%
Protein Expression
9%
Sildenafil
9%
Pregnancy
8%
Vasodilatation
7%
Oxygen
6%
Pulmonary Vasculature
6%
Guanylate Cyclase
6%
Immunofluorescence Test
6%
Pharmacology, Toxicology and Pharmaceutical Science
Hydrocortisone
78%
Phosphodiesterase V
72%
Persistent Pulmonary Hypertension
43%
Lung Dysplasia
40%
Lamb
38%
Glucocorticoid
36%
Pulmonary Hypertension
36%
Cyclic GMP
31%
Nitric Oxide
20%
Tamsulosin
18%
Fetus Risk
18%
Surfactant
18%
Reactive Oxygen Metabolite
17%
Alternative Complement Pathway C3 C5 Convertase
15%
Placebo
15%
Nuclear Factor
15%
Guanylate Cyclase
14%
Oxygen
12%
Vascular Remodeling
10%
Neonatal Pulmonary Hypertension
9%
Sildenafil
9%
Prematurity
9%
Heart Right Ventricle Hypertrophy
6%
Peripheral Vasodilating Agent
5%
Antioxidant
5%
Lung Disease
5%
C57BL 6 Mouse
5%